<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/">
<rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6843">
    <dcterms:title><![CDATA[<strong>Intranasal delivery of Quillaja brasiliensis saponin-based nanoadjuvants improve humoral immune response of influenza vaccine in aged mice</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[QUILLAJA BRASILIENSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[VACUNAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[NANOTECNOLOGIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[NANOPARTICULAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[MATRICES ISCOM]]></dcterms:subject>
    <dcterms:subject><![CDATA[VIRUS]]></dcterms:subject>
    <dcterms:subject><![CDATA[INFLUENZA]]></dcterms:subject>
    <dcterms:subject><![CDATA[VIA INTRANASAL]]></dcterms:subject>
    <dcterms:subject><![CDATA[RATONES ENVEJECIDOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2024]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Increasing the effectiveness of vaccines against respiratory viruses is particularly relevant for the elderly, since they are prone to develop serious infections due to comorbidities and the senescence of the immune system. The addition of saponin-based adjuvants is an interesting strategy to increase the effectiveness of vaccines. We have previously shown that ISCOM matrices from Q. brasiliensis (IMXQB) are a safe and potent adjuvant. In this study, we evaluated the use of IMXQB as an adjuvant for the seasonal trivalent influenza vaccine (TIV) in an aged mice model. Herein, we show that subcutaneous injection of the adjuvanted vaccine promoted higher titers of IgM, IgG (and isotypes), and serum hemagglutination inhibition titers (HAI). Notably, aged mice immunized by intranasal route also produced higher IgG (and isotypes) and IgA titers up to 120 days after priming, as well as demonstrating an improvement in the HAI antibodies against the TIV. Further, experimental infected aged mice treated once with sera from adult na&iuml;ve mice previously immunized with TIV-IMXQB subcutaneously successfully controlled the infection. Overall, TIV-IMXQB improved the immunogenicity compared to TIV by enhancing systemic and mucosal immunity in old mice conferring a faster recovery after the H1N1pdm09-like virus challenge. Thus, IMXQB nanoparticles may be a promising platform for next-generation viral vaccines.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Silveira, Fernando</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Garc&iacute;a, Florencia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Garc&iacute;a, Gabriel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Chabalgoity, Jos&eacute; A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rossi, Silvina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Baz, Mariana</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[<span data-sheets-formula-bar-text-style="font-size:13px;color:#000000;font-weight:normal;text-decoration:none;font-family:'Arial';font-style:normal;text-decoration-skip-ink:none;">Vaccines, v. 12, n&ordm; 8, 2024. -- e902</span>]]></dcterms:source>
    <dcterms:publisher><![CDATA[MDPI]]></dcterms:publisher>
    <dcterms:date><![CDATA[2024]]></dcterms:date>
    <dcterms:rights><![CDATA[<div class="element-text">
<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
</div>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[18 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[<span data-sheets-formula-bar-text-style="font-size:13px;color:#000000;font-weight:normal;text-decoration:none;font-family:'Arial';font-style:normal;text-decoration-skip-ink:none;">10.3390/vaccines12080902</span>]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6584">
    <dcterms:title><![CDATA[<strong>ISCOM-Matrices Nanoformulation Using the Raw Aqueous Extract of Quillaja lancifolia (Q. brasiliensis)</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[QUILLAJA BRASILIENSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[SAPONINAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[VACUNAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[NANOTECNOLOGIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2022]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Quillaja saponins have an intrinsic capacity to interact with membrane lipids that self-assembles in nanoparticles (immu nostimulating complexes or ISCOM-matrices) with outstanding immunoadjuvant activity and low toxicity profle. However, the expensive and laborious purifcation processes applied to purify Quillaja saponins used to assemble ISCOM-matrices show an important drawback in the large-scale use of this vaccine adjuvant. Thus, in this study, we describe a protocol to appropriately formulate ISCOM-matrices using the raw aqueous extract (AE) of Quillaja lancifolia leaves. In the presence of lipids, AE was able to self-assemble in nanostructures that resembles immunostimulating complexes (ISCOM). These nega tively charged nanoparticles of approximately 40 nm were characterized by transmission electron microscopy and dynamic light scattering. In addition, well-known saponins with remarkable immunoadjuvant activity, as QS-21, were detected into nanoparticles. Thus, the easier, robust, cheaper, and environmentally friendly method developed here may be an alternative to the classical methods for ISCOM-matrices production that use high-purifed saponins.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Cibulski, Samuel Paulo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Amorim de Souza, Thalisson</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Raimundo, Joanda Paola</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mangueira Nascimento, Yuri</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Silva Abreu, Lucas</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Su&aacute;rez Olivera, Norma</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?fff9206a83386ce414ac2d4d58c00b9b92cfe2c0daf8af28bce72589d7caec886367158e5f173950e50660448119dda8d7440f347a7eeb69978a04e756a13f77" target="_blank"><strong>Miraballes, Iris</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Roehe, Paulo Michael</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Machado de Ara&uacute;jo, Demetrius Antonio</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fechine Tavares, Josean</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Sobral da Silva, Marcelo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Silveira, Fernando</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[BioNanoScience v. 12, 2022. -- pp. 1166&ndash;1171]]></dcterms:source>
    <dcterms:publisher><![CDATA[Springer]]></dcterms:publisher>
    <dcterms:date><![CDATA[2022]]></dcterms:date>
    <dcterms:rights><![CDATA[<p dir="ltr"><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p dir="ltr">(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p dir="ltr"><strong>La legislaci&oacute;n uruguaya protege el derecho de autor</strong>&nbsp;sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<span id="docs-internal-guid-9d2103f7-7fff-c813-00c7-2528fd4891ff"><strong>ADVERTENCIA:</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</span>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[6 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.1007/s12668-022-01023-8]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6524">
    <dcterms:title><![CDATA[<strong>Structure elucidation of Triterpenoid Saponins found in an immunoadjuvant preparation of Quillaja brasiliensis using mass spectrometry and 1H and 13C NMR spectroscopy</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[SAPONINAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[QUILLAJA BRASILIENSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ESPECTROSCOPIA DE MASAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ISOMEROS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ESPECTROSCOPIA DE RESONANCIA MAGNETICA NUCLEAR]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2022]]></dcterms:subject>
    <dcterms:abstract><![CDATA[An immunoadjuvant preparation (named Fraction B) was obtained from the aqueous extract of Quillaja brasiliensis leaves, and further fractionated by consecutive separations with silica flash MPLC and reverse phase HPLC. Two compounds were isolated, and their structures elucidated using a combination of NMR spectroscopy and mass spectrometry. One of these compounds is a previously undescribed triterpene saponin (Qb1), which is an isomer of QS-21, the unique adjuvant saponin employed in human vaccines. The other compound is a triterpene saponin previously isolated from Quillaja saponaria bark, known as S13. The structure of Qb1 consists of a quillaic acid residue substituted with a -D-Galp-(1!2)-[ -D-Xylp-(1!3)]- -D-GlcpA trisaccharide at C3, and a -D-Xylp-(1!4)- -L-Rhap-(1!2)-[ -L-Arap-(1!3)]- -D-Fucp moiety at C28. The oligosaccharide at C28 was further substituted at O4 of the fucosyl residue with an acyl group capped with a -D-Xylp residue.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Wallace, Federico</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fontana, Carolina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ferreira, Fernando</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Olivaro, Cristina</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Molecules 2022 v. 27, 2022. -- e2402]]></dcterms:source>
    <dcterms:publisher><![CDATA[MDPI]]></dcterms:publisher>
    <dcterms:date><![CDATA[2022]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><span><strong>Informaci&oacute;n sobre Derechos de Autor</strong></span></p>
<p><span>(Por favor lea este aviso antes de abrir los documentos u objetos)</span></p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho de autor</strong><span>&nbsp;sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</span></p>
<p><strong>ADVERTENCIA:</strong><span>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</span></p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.3390/molecules27082402]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/5972">
    <dcterms:title><![CDATA[<strong>Structural characterisation of new immunoadjuvant saponins from leaves and the first study of saponins from the bark of Quillaja brasiliensis by liquid chromatography electrospray ionisation ion trap mass spectrometry</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[SAPONINAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANALISIS DE MONOSACARIDOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ESPECTROMETRIA DE MASAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[QUILLAJA BRASILIENSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2019]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Introduction Quillaja brasiliensis (St. A. ‐Hil. &amp; Tul) Mart (Quillajaceae) is a species native to South America, which is rich in saponins. Saponins are used in different industries, so there is a constant demand for this type of compound. Based on the wide range of applications for the saponins found in this species, notably as immunoadjuvants, we conducted a comprehensive study of this tree and its saponins. Objective The purpose of this work is to complete the characterisation of the immunoadjuvant saponin fraction from Q. brasiliensis leaves and further study the saponin fraction obtained from Q. brasiliensis bark. Methodology Saponin fractions were studied using mass spectrometry in combination with classical methods of monosaccharide and methylation analysis. We performed direct infusion and liquid chromatography/electrospray ionisation ion trap multiple‐stage mass spectrometry (DI‐ESI‐IT‐MSn and LC‐ESI‐IT‐MS2). Results Seventy‐five saponins, 21 from leaves and 54 from bark, were tentatively identified according to their molecular mass, fragmentation pattern and chromatographic behaviour. This work represents the first investigation of saponins from the bark of Q. brasiliensis and some of them presented new structural motifs not previously reported in the genus Quillaja. Conclusion The efficiency and selectivity of the data dependent LC‐MS2 method allowed the rapid profiling of saponins from Q. brasiliensis. The results of the monosaccharide and methylation analysis performed in saponins from Q. brasiliensis fractions and Q. saponaria Molina (Quillajaceae) fraction gives further support to the structures proposed according to the mass spectral data, validating the strategy used in the present work.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Wallace, Federico</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Bennadji, Zohra</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwiGk83Y3L_mAhVuIbkGHbYXCOwQFjAAegQIAxAH&amp;url=https%3A%2F%2Fexportcvuy.anii.org.uy%2FCvEstatico%2F%3FurlId%3D83599915c2932d7ab87a1eb547042501ece38f26e6163f01a8a8aa642db67da505e5a1cb01f616571f4202b7d0c69a4823a7bdd022d839b2ff14f463b04195b3%26formato%3Dpdf%26convocatoria%3D21&amp;usg=AOvVaw1XjRVBgSdzxxVH1EdfAlFh" target="_self"><strong>Ferreira, Fernando.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Olivaro, Cristina</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Phytochemical Analysis v. 30, no.6, 2019. -- p. 644-652]]></dcterms:source>
    <dcterms:publisher><![CDATA[Wiley]]></dcterms:publisher>
    <dcterms:date><![CDATA[2019]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI:10.1002/pca.2837]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/5445">
    <dcterms:title><![CDATA[<strong>Quillaja brasiliensis saponin-based nanoparticulate adjuvants are capable of triggering early immune responses</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[SAPONINAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[VACUNAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[INMUNOLOGIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[QUILLAJA BRASILIENSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2018]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Commercially available saponins are extracted from Quillaja saponaria barks, being Quil A&reg; the most widely used. Nanoparticulate immunostimulating complexes (ISCOMs or ISCOMATRIX) formulated with these, are able to stimulate strong humoral and cellular immune responses. Recently, we formulated novel ISCOMs replacing QuilA&reg; by QB-90 (IQB-90), a Quillaja brasiliensis leaf-extracted saponin fraction, and reported that IQB-90 improved antigen uptake, and induced systemic and mucosal antibody production, and T-cell responses. However, its mechanism of action remains unclear. In this study we provide a deeper insight into the immune stimulatory properties of QB-90 and ISCOMATRIX-like based on this fraction (IMXQB-90). We show herein that, when used as a viral vaccine adjuvant, QB-90 promotes an &ldquo;immunocompetent environment&rdquo;. In addition, QB-90 and IMXQB-90 induce immune-cells recruitment at draining-lymph nodes and spleen. Subsequently, we prove that QB-90 or IMXQB-90 stimulated dendritic cells secret IL-1&beta; by mechanisms involving Caspase-1/11 and MyD88 pathways, implying canonical inflammasome activation. Finally, both formulations induce a change in the expression of cytokines and chemokines coding genes, many of which are up-regulated. Findings reported here provide important insights into the molecular and cellular mechanisms underlying the adjuvant activity of Q. brasiliensis leaf-saponins and its respective nanoparticles.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Cibulski, Samuel Paulo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rivera Patr&oacute;n, Mariana.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mourglia Ettlin, Gustavo Daniel.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Casaravilla, Cecilia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Alves Yendo, Anna Carolina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fett Neto, Arthur Germano</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Chabalgoity, Jos&eacute; Alejandro</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Moreno, Mar&iacute;a</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Roehe, Paulo Michel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Silveira, Fernando</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Scientific Reports v. 8, no. 1, 2018. --15p.-- e13582]]></dcterms:source>
    <dcterms:publisher><![CDATA[Springer Nature Limited]]></dcterms:publisher>
    <dcterms:date><![CDATA[2018]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1038/s41598-018-31995-1]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/5444">
    <dcterms:title><![CDATA[<strong>Leaf saponins of Quillaja brasiliensis enhance long-term specific immune responses and promote dose-sparing effect in BVDV experimental vaccines</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[SAPONINAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[INMUNOLOGIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[QUILLAJA BRASILIENSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[VACUNAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2018]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Saponin-based adjuvants are promising adjuvants that enhance both humoral and T-cell-mediated immunity. One of the most used natural products as vaccine adjuvants are Quillaja saponaria bark saponins and its fraction named Quil A&reg;. Despite that, its use has been restricted for human use due to safety issues. As an alternative, our group has been studying the congener species Quillaja brasiliensis saponins and its performance as vaccine adjuvants, which have shown to trigger humoral and cellular immune responses comparable to Quil A&reg; but with milder side effects. Here, we studied a semi purified aqueous extract (AE) and a previously little characterized saponin-enriched fraction (QB-80) from Q. brasiliensis as vaccine adjuvants and an inactivated virus (bovine viral diarrhea virus, BVDV) antigen co-formulated in experimental vaccines in mice model. For the first time, we show the spectra pattern of the Q. brasiliensis saponins by MALDI-TOF, a novel and cost-effective method that could be used to characterize different batches during saponins production. Both AE and QB-80 exhibited noteworthy chemical similarities to Quil A&reg;. In addition, the haemolytic activity and toxicity were assessed, showing that both AE and QB-80 were less toxic than Quil A&reg;. When subcutaneously inoculated in mice, both fractions promoted long-term strong antibody responses encompassing specific IgG1 and IgG2a, enhanced the avidity of IgG antibodies, induced a robust DTH reaction and significantly increased IFN-ɣ production in T CD4+ and T CD8+ cells. Furthermore, we have proven herein that AE has the potential to promote dose-sparing, substantially reducing the dose of antigen required for the BVDV vaccines and still eliciting a mixed Th1/Th2 strong immune response. Based on these results, and considering that AE is a raw extract, easier and cheaper to produce than commercially available saponins, this product can be considered as candidate to be escalated from experimental to industrial uses.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Cibulski, Samuel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rivera Patr&oacute;n, Mariana.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Su&aacute;rez, Norma</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Pirez, Macarena</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rossi, Silvina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Yendo, Anna Carolina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>de Costa, Fernanda</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gosmann, Grace</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fett Neto, Arthur</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Roehe, Paulo Michel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Silveira, Fernando</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Vaccine&nbsp; v. 36, 2018. -- p. 55-65]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2018]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1016/j.vaccine.2017.11.030]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/4913">
    <dcterms:title><![CDATA[<strong>Analysis of an immunoadjuvant saponin fraction from Quillaja brasiliensis leaves by electrospray ionization ion trap multiple-stage mass spectrometry</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[PRODUCTOS NATURALES]]></dcterms:subject>
    <dcterms:subject><![CDATA[QUILLAJA BRASILIENSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[SAPONINAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2017]]></dcterms:subject>
    <dcterms:abstract><![CDATA[An immunoadjuvant saponin fraction from Quillaja brasiliensis leaves was investigated by direct infusion and liquid chromatography/electrospray ionization ion trap multiple-stage mass spectrometry in negative ion mode (DI-ESI-IT-MSn and LC-ESI-IT-MSn). The aglycone and the sequence of the oligosaccharide residues at C-3 and C-28 were characterized based on MS2 and MS3 experiments of the [MH]&minus; ions. According to their [MH]&minus; ions, characteristic product ions and retention times, 27 bidesmosidic saponins, bearing four types of triterpenic aglycones, were tentatively identified.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Wallace, Federico</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Bennadji, Zohra</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curiculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=06ea8350d5f6e14cde5d4fa22f5ff626" target="_blank"><strong>Ferreira, Fernando</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Olivaro, Cristina</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Phytochemistry Letters |g v. 20, 2017. -- p. 228-233]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2017<br />
]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&egrave;s]]></dcterms:language>
    <dcterms:type><![CDATA[Artículo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1016/j.phytol.2017.04.020]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/4510">
    <dcterms:title><![CDATA[<strong>Quillaja brasiliensis saponins induce robust humoral and cellular responses in a bovine viral diarrhea virus vaccine in mice</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[VACUNAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[VIRUS]]></dcterms:subject>
    <dcterms:subject><![CDATA[RATONES]]></dcterms:subject>
    <dcterms:subject><![CDATA[QUILLAJA BRASILIENSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2016]]></dcterms:subject>
    <dcterms:abstract><![CDATA[A saponin fraction extracted from Quillaja brasiliensis leaves (QB-90) and a semi-purified aqueous extract (AE) were evaluated as adjuvants in a bovine viral diarrhea virus (BVDV) vaccine in mice. Animals were immunized on days 0 and 14 with antigen plus either QB-90 or AE or an oil-adjuvanted vaccine. Two-weeks after boosting, antibodies were measured by ELISA; cellular immunity was evaluated by DTH, lymphoproliferation, cytokine release and single cell IFN-&gamma; production. Serum anti-BVDV IgG, IgG1 and IgG2b were significantly increased in QB-90- and AE-adjuvanted vaccines. A robust DTH response, increased splenocyte proliferation, Th1-type cytokines and enhanced production of IFN-&gamma; by CD4(+) and CD8(+) T lymphocytes were detected in mice that received QB-90-adjuvanted vaccine. The AE-adjuvanted preparation stimulated humoral responses but not cellular immune responses. These findings reveal that QB-90 is capable of stimulating both cellular and humoral immune responses when used as adjuvant.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Cibulski, Samuel Paulo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Silveira, Fernando</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mourglia Ettlin, Gustavo Daniel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fumaco Teixeira, Thais</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fernandes dos Santos, Helton</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Yendo, Anna Carolina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>de Costa, Fernanda</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fett-Netto, Arthur Germano</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gossmann, Grace</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Roehe, Paulo Michel</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Comparative Immunology, Microbiology and Infectious Diseases v. 45, 2016. -- p. 1-8]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2016]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protegel derech eo</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong> ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ing&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI:10.1016/j.cimid.2016.01.004]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/4323">
    <dcterms:title><![CDATA[<strong>A rabies vaccine adjuvanted with saponins from leaves of the soaptree (Quillaja brasiliensis) induces specific immune responses andprotects against lethal challenge</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[VACUNAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[CONEJOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[SAPONINAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[QUILLAJA BRASILIENSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2016]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Quillaja brasiliensis (Quillajaceae) is a saponin producing species native from southern Brazil and Uruguay. Its saponins are remarkably similar to those of Q. saponaria, which provides most of the saponins used as immunoadjuvants in vaccines. The immunostimulating capacities of aqueous extract (AE) and purified saponin fraction (QB-90) obtained from leaves of Q. brasiliensis were favorably comparable to those of a commercial saponin-based adjuvant preparation (Quil-A&reg;) in experimental vaccines against bovine herpesvirus type 1 and 5, poliovirus and bovine viral diarrhea virus in mice model. Herein, the immunogenicity and protection efficacy of rabies vaccines adjuvanted with Q. brasiliensis AE and its saponin fractions were compared with vaccines adjuvanted with either commercial Quil-A or Alum. Mice were vaccinated with one or two doses (on days 0 and 14) of one of the different vaccines and serum levels of total IgG, IgG1 and IgG2a were quantified over time. A challenge experiment with a lethal dose of rabies virus was carried out with the formulations. Viral RNA detection in the brain of mice was performed by qPCR, and RNA copy-numbers were quantified using a standard curve of in vitro transcribed RNA. All Q. brasiliensis saponin-adjuvanted vaccines significantly enhanced levels of specific IgG isotypes when compared with the no adjuvant group (P &le; 0.05). Overall, one or two doses of saponin-based vaccine were efficient to protect against the lethal rabies exposure. Both AE and saponin fractions from Q. brasiliensis leaves proved potent immunological adjuvants in vaccines against a lethal challenge with a major livestock pathogen, hence confirming their value as competitiv]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Yendo, Anna Carolina A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>De Costa, Fernanda</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Cibulski, Samuel P.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Teixeira, Thais F.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Colling, Luana C.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mastrogiovanni, Mauricio</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=1502d6d114aace9e148166840e515f38" target="_blank"><strong>Soul&eacute;, Silvia</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Roehe, Paulo M.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gosmann, Grace</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=06ea8350d5f6e14cde5d4fa22f5ff626" target="_blank"><strong>Ferreira, Fernando</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fett-Neto, Arthur G.</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Vaccine v. 34, 2016. -- p. 2305-2311]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2016]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong> ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Artículo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1016/j.vaccine.2016.03.070]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3945">
    <dcterms:title><![CDATA[<strong>Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[SAPONINAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[QUILLAJA BRASILIENSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2016]]></dcterms:subject>
    <dcterms:abstract><![CDATA[<p>In the last decades, significant efforts have been dedicated to the search for novel vaccine adjuvants. Inthis regard, saponins and its formulations as &ldquo;immunostimulating complexes&rdquo; (ISCOMs) have shown to becapable of stimulating potent humoral and cellular immune responses, enhanced cytokine production andactivation of cytotoxic T cells. The immunological activity of ISCOMs formulated with a saponin fractionextracted from Quillaja brasiliensis (QB-90 fraction) as an alternative to classical ISCOMs based on Quil A&reg;(IQA) is presented here. The ISCOMs prepared with QB-90, named IQB-90, typically consist of 40&ndash;50 nm,spherical, cage-like particles, built up by QB-90, cholesterol, phospholipids and antigen (ovalbumin, OVA).These nanoparticles were efficiently uptaken in vitro by murine bone marrow-derived dendritic cells.Subcutaneously inoculated IQB-90 induced strong serum antibody responses encompassing specific IgG1and IgG2a, robust DTH reactions, significant T cell proliferation and increases in Th1 (IFN- and IL-2)cytokine responses. Intranasally delivered IQB-90 elicited serum IgG and IgG1, and mucosal IgA responsesat distal systemic sites (nasal passages, large intestine and vaginal lumen). These results indicate that IQB-90 is a promising alternative to classic ISCOMs as vaccine adjuvants, capable of enhancing humoral andcellular immunity to levels comparable to those induced by ISCOMs manufactured with Quillaja saponariasaponins.</p>]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Cibulski, Samuel Paulo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mourglia-Ettlin, Gustavo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fumaco Teixeira, Thais</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Quirici, Leonora</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Roehe, Paulo Michel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curr&iacute;culum vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=06ea8350d5f6e14cde5d4fa22f5ff626" target="_blank"><strong>Ferreira, Fernando</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Silveira, Fernando</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Vaccine v.34, 2016. -- p. 1162-1171]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2016]]></dcterms:date>
    <dcterms:rights><![CDATA[<p align="LEFT"><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p style="margin-bottom: 0cm;"><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
<p>&nbsp;</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[http://dx.doi.org/10.1016/j.vaccine.2016.01.029]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/993">
    <dcterms:title><![CDATA[<strong>Quillaja brasiliensis saponins are less toxic than Quil A and have similar properties when used as an adjuvant for a viral antigen preparation</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ANTIVIRALES]]></dcterms:subject>
    <dcterms:subject><![CDATA[QUILLAJA BRASILIENSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2011]]></dcterms:subject>
    <dcterms:abstract><![CDATA[In this study, a preparation of saponins (QB-90U) extracted from leaves of Quillaja brasiliensis collected in Uruguay was evaluated as a vaccine adjuvant by comparison with alum and the well known saponinbased adjuvant, Quil A. The haemolytic activity and cellular toxicity of the saponin preparations were also evaluated. QB-90U was only slightly haemolytic and showed a low cytotoxicity when compared to Quil A. The adjuvant properties of QB-90U were assayed by sub-cutaneous immunization of mice with a preparation of inactivated bovine herpesvirus 5 (BoHV-5) either with no adjuvant or adjuvanted with QB-90U, Quil A or alum. Serum levels of anti-BoHV-5 IgG, IgG1, IgG2a, IgG2b and also IgG3 were significantly increased by QB-90U and were of the same order as those elicited by Quil A. Furthermore, high titres of neutralizing antibodies were found to be present in the serum of immunized animals from both groups. The cellular response induced by QB-90U did also reproduce the one elicited by Quil A. In fact, a robust DTH response was observed in mice immunized with both saponin preparations; as well as increased splenocytes levels of Th1-type cytokines, namely IFN- and IL-2. Taken together, the above results confirm and extend our previous observation regarding the similarity of the responses elicited by Quil A and the saponin preparation from Q. brasiliensis (Fleck et al., 2006) and indicate that QB-90U is worth of further studies as a safe and potent vaccine adjuvant.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Silveira, F.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Cibulski, S. P.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Varela, A. P.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Marques, J. M.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Chabalgoity, Alejandro</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>de Costa, F.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Yendo, A. C. A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gosman, G.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Roehe, P. M.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curr&iacute;culum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=9664a257b8e611abc245a6f6ef902c2a" target="_blank"><strong>Fern&aacute;ndez, C.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ferreira Chiesa, Fernando</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Vaccine v. 29, no. 49, 2011. -- p. 9177-9182]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2011]]></dcterms:date>
    <dcterms:rights><![CDATA[<p align="LEFT"><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[doi:10.1016/j.vaccine.2011.09.137]]></dcterms:identifier>
</rdf:Description></rdf:RDF>
